Data Integrity, ALCOA+ & Part 11 / Annex 11 – Pharma GMP

Audit Trail Review in GMP: Designing a Practical, Risk-Based Program

digi — Fri, 21 Nov 2025 21:06:11 +0000

Audit Trail Review in GMP: Designing a Practical, Risk-Based Program Audit Trail Review in GMP: Designing a Practical, Risk-Based Program In the pharmaceutical manufacturing industry, maintaining data integrity is a foundational regulatory expectation demanded by authorities such as the FDA, EMA, and MHRA. Integral to this objective is the implementation of effective and practical audit...

Common Data Integrity Failures in QC Labs and How to Prevent Them

digi — Fri, 21 Nov 2025 21:09:11 +0000

Common Data Integrity Failures in QC Labs and How to Prevent Them Understanding and Preventing Common Data Integrity Failures in QC Laboratories Data integrity is a foundation stone in pharmaceutical manufacturing and quality control. Ensuring the accuracy, completeness, and reliability of data generated in Quality Control (QC) laboratories supports compliance with GxP principles and regulatory...

How to Perform a Data Integrity Risk Assessment for Critical GMP Systems

digi — Fri, 21 Nov 2025 21:12:11 +0000

How to Perform a Data Integrity Risk Assessment for Critical GMP Systems Step-by-Step Guide: Performing a Data Integrity Risk Assessment for Critical GMP Systems Ensuring data integrity is a fundamental requirement within pharmaceutical Good Manufacturing Practice (GMP). Considering the regulatory mandates under 21 CFR Part 11 in the US, Annex 11 in the EU, and...

Building a Site-Wide Data Integrity Governance Model for GMP Environments

digi — Fri, 21 Nov 2025 21:15:11 +0000

Building a Site-Wide Data Integrity Governance Model for GMP Environments Step-by-Step Guide to Building a Site-Wide Data Integrity Governance Model for GMP Environments In the pharmaceutical industry, maintaining data integrity across all manufacturing and control systems is a regulatory imperative and a cornerstone of product quality and patient safety. Robust governance models enable organizations to...

Data Integrity 101 in Pharma: Applying ALCOA+ Across All GxP Records

digi — Fri, 21 Nov 2025 21:18:11 +0000

Data Integrity 101 in Pharma: Applying ALCOA+ Across All GxP Records Ensuring Complete Data Integrity by Applying ALCOA+ in Pharmaceutical GxP Records Data integrity is a fundamental principle in pharmaceutical manufacturing and clinical operations, underpinning regulatory compliance, product quality, and patient safety. The concept of data integrity extends beyond mere accuracy to encompass completeness, consistency,...

Controlling Shared Logins and Unauthorized Access in GxP Computer Systems

digi — Fri, 21 Nov 2025 21:21:11 +0000

Controlling Shared Logins and Unauthorized Access in GxP Computer Systems Step-by-Step Tutorial: Managing Shared Logins and Preventing Unauthorized Access in GxP Computer Systems Maintaining data integrity in regulated pharmaceutical environments demands rigorous control of user access to electronic systems. Shared logins and unauthorized access pose significant risks to the trustworthiness of GxP records, potentially violating...

Detecting and Investigating Backdating and Record Reconstruction in GMP

digi — Fri, 21 Nov 2025 21:24:11 +0000

Detecting and Investigating Backdating and Record Reconstruction in GMP Detecting and Investigating Backdating and Record Reconstruction in GMP: A Step-by-Step Tutorial Maintaining data integrity is paramount within pharmaceutical Good Manufacturing Practice (GMP) environments. The risks posed by intentional or unintentional manipulation of GxP records compromise not only regulatory compliance but also product quality and patient...

Data Integrity Remediation After an MHRA or FDA Inspection: Step-by-Step Approach

digi — Fri, 21 Nov 2025 21:27:11 +0000

Data Integrity Remediation After an MHRA or FDA Inspection: Step-by-Step Approach Step-by-Step Guide to Data Integrity Remediation After an MHRA or FDA Inspection Ensuring robust data integrity is paramount for pharmaceutical manufacturers and related stakeholders in the United States, United Kingdom, and European Union. Regulatory authorities such as the FDA, MHRA, and EMA place significant...

Managing Hybrid Paper–Electronic Systems Without Compromising Data Integrity

digi — Fri, 21 Nov 2025 21:30:11 +0000

Managing Hybrid Paper–Electronic Systems Without Compromising Data Integrity Step-by-Step Guide to Managing Hybrid Paper–Electronic Systems Without Compromising Data Integrity In the pharmaceutical industry, maintaining data integrity across all forms of recording media is critical to product quality, regulatory compliance, and patient safety. Hybrid paper–electronic systems—where both paper and electronic records coexist—remain prevalent in many pharmaceutical...

Applying ALCOA+ Principles to Paper Records in High-Volume Operations

digi — Fri, 21 Nov 2025 21:33:11 +0000

Applying ALCOA+ Principles to Paper Records in High-Volume Operations Step-by-Step Guide to Applying ALCOA+ Principles to Paper Records in High-Volume Pharmaceutical Operations Maintaining robust data integrity is critical in pharmaceutical manufacturing and related operations. The regulatory expectations set forth by authorities such as the FDA, EMA, and MHRA emphasize adherence to ALCOA+ principles to ensure...